tixagevimab/cilgavimab

Action and Spectrum

Drug Interaction

Adverse Reaction

Frequency defined:  

1-10% 

Cough 

Fatigue 

Headache 

<1% 

Myocardial infarction 

Cardiac failure 

Arrhythmia 

Cardiomyopathy 

Cardiorespiratory arrest 

Black Box Warning

Contraindication / Caution

Pregnancy / Lactation

Pregnancy consideration: Insufficient data is available 

Lactation: Excretion of the drug in human breast milk is unknown  

Pregnancy category: 

• Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester. 
• Category B: There is no evidence of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women. 
• Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women 
• Category D: There is adequate data available with sufficient evidence of human foetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits. 
• Category X: Drugs listed in this category outweigh risks over benefits. These category drugs should be prohibited for pregnant women. 
• Category N: No data is available for the drug under this category. 

Pharmacology

Adminstartion

Patient Information Leaflet

Patient information leaflet 

Generic Name: Tixagevimab/cilgavimab 

Pronounced: ticks” a gev’ i mab/sil gav’ i mab  

Why do we use Tixagevimab/cilgavimab? 

The antibodies tixagevimab and cilgavimab can neutralize the coronavirus and may shield against COVID-19.